Xphozah (Tenapanor) Dosage
The FDA-approved dosage of Xphozah (tenapanor) is 30 mg orally twice daily, taken just prior to the morning and evening meals. 1
Dosing Regimen
For chronic kidney disease patients on dialysis with hyperphosphatemia:
- Standard dose: 30 mg twice daily before the first and last meals of the day 1
- Monitor serum phosphorus levels and adjust dosage as needed to manage gastrointestinal tolerability 1
Important timing considerations:
- Take just prior to meals (not with or after meals) 1
- Do NOT take right before a hemodialysis session - instead, take before the next meal following dialysis to minimize diarrhea risk 1
- If a dose is missed, skip it and take the next dose at the regular time 1
Dose Titration in Clinical Practice
While the FDA-approved dose is 30 mg twice daily, clinical trials have demonstrated a dose-ranging approach:
- Starting dose in some studies: 5 mg twice daily, with gradual titration up to 30 mg twice daily based on serum phosphorus levels and tolerability 2, 3
- This stepwise approach may improve tolerability, as diarrhea (the most common adverse event) is dose-dependent 4
Critical Safety Considerations
Diarrhea is the primary dose-limiting adverse event:
- Occurs in 43-53% of patients at the 30 mg twice daily dose 1
- Most cases are mild-to-moderate and resolve over time or with dose reduction 1
- Severe diarrhea occurs in approximately 5% of patients and requires treatment discontinuation 1
- Can lead to dehydration and hyponatremia in <1% of patients 1
Contraindications:
- Children under 6 years of age (risk of severe dehydration) 1
- Known or suspected mechanical gastrointestinal obstruction 1
Alternative Indication: IBS-C
For irritable bowel syndrome with constipation (IBS-C), the FDA-approved dosage is 50 mg twice daily - this is a different indication and higher dose than for hyperphosphatemia 5. This dosing was established through phase 2b and phase 3 trials demonstrating moderate-certainty evidence for symptom relief 5.